Native name | |
|---|---|
| Simplified Chinese | 热景生物 |
| Traditional Chinese | 熱景生物 |
| Company type | Public |
| SSE: 688068 | |
| Founded | 2005 |
| Founder | Changqing Lin |
| Headquarters | Beijing [1] |
| Revenue | CN¥5.369 billion (2021) [2] |
| Website | www |
Hotgen Biotech (short for Beijing Hotgen Biotech Co., Ltd.), often simply referred to as Hotgen, [3] is a Chinese biological technology company [4] founded in 2005. It focuses on the manufacture of in-vitro diagnostic instruments [5] and reagents. [6] In September 2019, the company was listed on the Shanghai Stock Exchange. [7] During the novel coronavirus pandemic, it specialized in making 2019-nCoV antigen diagnostic products, [8] which obtained EU CE certification. [9]
Hotgen was formerly a constituent of the STAR 50 Index. [10] Headquartered in Beijing, it also established presences in foreign markets, such as the United Kingdom, [11] France, [12] and Germany. [13] The net profit of the company in 2021 exceeded 2.3 billion yuan, [14] an increase of more than sixteen times from the previous year. [15] In 2022, its RAT kits were distributed free of charge [16] by the Hong Kong Government to the public. [17] In November 2023, it attended the MEDICA Trade Fair in Düsseldorf. [18]
Hotgen was established by Changqing Lin in 2005. [19] In September 2019, it went public on the STAR Market, [20] with stock symbol 688068.SH. [21] In early 2021, its COVID antigen self-test kits gained market access in Germany. [22]
As of April 2021, Hotgen's market cap surpassed RMB 10 billion. [23] In March 2022, its RAT products were approved by the NMPA. [24] In November, the Hotgen COVID-19 Antigen Home Test received an EUA from the FDA. [25]